Total information dominance on cancer.
Every technology, target, product, company, institution, pathway, trial, pairing, roadmap, and idea in oncology, linked together. The state of the art, the history, and what is coming, for every cancer, with a plain-English TL;DR on every page.
3,948 linked objects, one page each. Every count is a link.
Whole corpus as JSONPatient or family
Start from your diagnosis. Plain English first, the technical layer one click away.
Clinician or researcher
Ranked, sortable, cited. Every number links to its source and every object to its neighbours.
Builder or investor
Where the field is stuck, who is working on it, and where the white space is.
Begin from your situation or your question: your cancer, your biomarkers, what to compare, where the cancer is in the body.
Every cancer, every way to detect and treat it, every drug, target, trial, and term. One page each, in plain English first.
What is happening and how strong the evidence is: dates, congress readouts, approvals, failures, resistance, and the supply chain behind the drugs.
The hospitals, universities, doctors, scientists, companies, countries, and funders behind the field, mapped and ranked with disclosed formulas.
Curated paths through the material, how the site works, and how to make it better.
Fronts of the war on cancer
Every way we see, measure or attack a tumour, grouped. Each schematic is a working model, not to scale.
Ways of seeing cancer inside the body without cutting, from X-rays to tracers that light up a single protein.
Tests on tissue and blood that say what kind of cancer it is, what is driving it, and which drugs might work.
Finding cancer before it causes symptoms, when it is most curable.
Removing or destroying tumours physically, increasingly with robots, image guidance, and heat or cold instead of a knife.
Using focused beams or radioactive particles to kill tumour cells while sparing healthy tissue.
Drugs that kill fast-dividing cells. Still the backbone of many cures, and now the warhead inside smarter drugs.
Drugs designed to switch off a specific broken protein that a cancer depends on.
An antibody that finds the tumour, carrying a tiny dose of very strong chemotherapy that is released only inside it.
Helping the patient's own immune system recognise and destroy the cancer.
Taking immune cells, engineering or expanding them, and giving them back as a living drug.
A molecule that homes to the tumour carries a radioactive atom. The same molecule with a different atom lets you see the tumour first.
Cutting off the hormones that some cancers, especially breast and prostate, need to grow.
Changing how genes are read rather than the genes themselves.
Everything that keeps a patient well enough to receive treatment, and well afterwards.
Software that reads scans and slides, predicts outcomes, designs drugs, and matches patients to trials.
The tools used to find the next drug: gene screens, organoids, models in mice, and AI.
Stopping cancer from starting: vaccines, germline testing, lifestyle, and preventive drugs or surgery.
Machines that treat cancer with electric fields, heat, or sound rather than chemicals.
What people eat, drink, weigh and do affects who gets cancer, how treatment goes, and who relapses. This front studies that with the rigour of a drug trial.
What is new
Generated from the corpus at each build: approvals by product, and the latest milestone recorded for each cancer.
Approvals in 2026
34 products- AcalabrutinibFixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)
- ArteraAI BreastRisk stratification in early-stage HR+/HER2- invasive breast cancer
- AtezolizumabAdjuvant muscle-invasive bladder cancer, ctDNA-positive after cystectomy
- BelzutifanAdjuvant clear-cell RCC with pembrolizumab
- CamizestrantHR+/HER2- advanced breast cancer with an emergent ESR1 mutation on AI + CDK4/6, with a CDK4/6 inhibitor (accelerated, 4 Sep 2026)
- CapivasertibPTEN-deficient metastatic prostate cancer with abiraterone
- DaratumumabWith teclistamab after ≥1 line (MajesTEC-3); high-risk smouldering myeloma (AQUILA)
- DaraxonrasibMetastatic pancreatic cancer (previously treated)
- Datopotamab deruxtecanFirst-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible
- Decitabine + cedazuridine (oral)Newly diagnosed AML, unfit for intensive induction, with venetoclax (ASCERTAIN-V)
Latest milestone, by cancer
2026- Acute lymphoblastic leukaemiaSubcutaneous blinatumomab and Interfant-21 progressSubcutaneous blinatumomab trials (including the first in mixed-phenotype leukaemia) aim to replace continuous infusion; infant trials integrate blinatumomab.
- Acute myeloid leukaemiaFirst all-oral AML regimenDecitabine-cedazuridine + venetoclax approved 13 May 2026 (ASCERTAIN-V, CR 41.6%).
- Biliary tract cancer (cholangiocarcinoma)Zenocutuzumab approved for NRG1-fusion cholangiocarcinoma; HERIZON-BTC-302 enrolling
- Bladder & urothelial cancerIMvigor011 ctDNA-guided atezolizumab and POTOMAC durvalumab + BCG approved; cretostimogene BLA under way
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)Pivekimab sunirine approvedCD123 ADC (CADENZA), FDA May 2026.
- Cervical cancerWorld Health Assembly calls for accountable elimination systems; sac-TMT and TIL trials in recurrent disease
- Chronic lymphocytic leukaemiaFirst US all-oral fixed-duration regimen; sonrotoclax US approval (MCL); BTK degrader phase 3Acalabrutinib-venetoclax approved 19 February; sonrotoclax accelerated approval 13 May; CaDAnCe-304 and CELESTIAL-TNCLL enrolling.
- Colorectal cancerBREAKWATER FOLFIRI cohort and full approval; AZUR-1 priority review; T-DXd and RAS(ON) inhibitors advance
- Diffuse large B-cell lymphomafrontMIND published in Lancet; EPCORE DLBCL-1 misses OS; frontline bispecific data (EPCORE DLBCL-2) at EHA
- Endometrial cancerSelinexor maintenance fails (XPORT-EC-042)Post-hoc TP53-wild-type subgroup hypothesis not confirmed.
Spotlight: triple-negative breast cancer
The deepest page on the site, and the template every cancer page is growing into.
A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that.
Curative-intent: chemo-immunotherapy (KEYNOTE-522) cures more patients than ever; pCR ~65%. Adjuvant PARP inhibitor for BRCA carriers.
Bispecific ADC succeeds; first-line ADC approvals: Iza-bren phase 3 positive (Feb 2026); FDA approves Dato-DXd and sacituzumab govitecan first line (Q2 2026).
ADC sequencing: does a second TOP1-payload ADC work after the first? SATEEN/BRE-354 suggest limited efficacy; chemotherapy interposition debated.
Roadmaps
History to horizon for each technology family.
Twenty-five years of trying to make chemotherapy hit only cancer cells, from the unstable first ADC to today's third-generation blockbusters and the fourth generation now in trials.
How AI is moving from single-task readers of scans and slides towards systems that weigh everything about a patient, and what regulators and evidence still require.
From a cure for some leukaemias in 2017 to the first solid-tumour CAR-T and the prospect of making CAR-T inside the body with an injection.
From mammograms and colonoscopies to a single blood draw that might screen for dozens of cancers, with the FDA's first decision imminent.
A 130-year arc from injecting bacteria into tumours to releasing immune brakes, and now to designing the immune response itself with vaccines, engagers, and cells.
The most important cancer gene was declared undruggable for 40 years. Then a pocket was found, and now a pan-RAS drug is in phase 3 for pancreatic cancer.
From a sugar tracer that lights up most cancers to tracers that show a single protein, a stromal cell type, or the immune cells inside a tumour.
Three different ways a cancer stops killing someone: stop it before it starts, remove every last cell, or hold it in check for life. Each needs different technology.
A horizon map of the wilder ideas in cancer, sorted by how close they are to mattering, with the reason each one might never arrive.
Eighty years from radioactive iodine for thyroid cancer to alpha-emitting drugs for prostate and neuroendocrine cancers, with isotope supply as the limiting factor.
How triple-negative breast cancer went from the subtype with no targeted therapy to one with immunotherapy, PARP inhibitors, three ADCs, and a positive bispecific ADC in six years.
One target, three approved-or-nearly-approved drugs, and a fourth wave. How TROP2 went from an obscure trophoblast antigen to the centre of breast and lung cancer treatment.
The attempt to build a computer model of a cell good enough to predict what a drug or mutation will do before anyone runs the experiment.
Frontier technologies
Early, unproven, and worth watching.
An antibody given alongside an ADC that mops up the poison once it leaks into the bloodstream, so the ADC can hit the tumour with fewer side effects.
Using machine learning to pick targets, design molecules and antibodies, and predict which ADC will work.
Actinium-225 releases four alpha particles as it decays, but the daughters escape and irradiate the kidneys and salivary glands. Nanocarriers try to hold them in place.
An ADC that carries a gene-silencing strand instead of a chemotherapy, so it can switch a protein off rather than poison the cell.
Upgraded CAR-T cells that also secrete immune boosters, resist exhaustion, or only fire when two signals are present.
Radioactive atoms that spray very short-range electrons, lethal only if the atom sits on or inside the cell's DNA.
Using viruses that infect bacteria, not human cells, as programmable delivery shells for cancer drugs and vaccines.
An ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue.